Douglas V. Faller, MD, PhD
Professor
Boston University School of Medicine
Dept of Medicine
Hematology & Medical Oncology

MD, Harvard University
PhD, Massachusetts Institute of Technology



Dr. Douglas Faller is a Boston-based physician/scientist with over 15 years of pharmaceutical and biotech experience involving discovery, pre-clinical and clinical development of small molecules for several therapeutic areas, specializing in oncology and hematology, plus over 25 years of academic clinical and laboratory research experience in the fields of drug discovery and development, oncology and hematology, cell and molecular biology, management of professionals, including the programmatic organization of large groups of scientists, and development of research and drug development programs.

Active Staff Privileges
Boston Medical Center
Medicine
Hematology & Medical Oncology



BOSTON UNIVERSITY CROSS-DISCIPLINARY TRAINING IN NANOTECHNOLOGY FOR CANCER
09/01/2010 - 07/31/2016 (Co-PI)
NIH/National Cancer Institute
5R25CA153955-05

TARGETING N-RAS AS A THERAPEUTIC APPROACH FOR MELANOMA
05/01/2012 - 04/30/2016 (PI)
Melanoma Research Alliance

PKC-INHIBITORS AS TARGETED THERAPEUTICS FOR SYSTEMIC SCLEROSIS
01/15/2014 - 01/14/2016 (PI)
Scleroderma Foundation

NON-ONCOGENE ADDICTION AS A TARGETED THERAPY FOR PANCREATIC CANCER
01/01/2013 - 12/31/2015 (PI)
NIH/National Cancer Institute
5R21CA164245-02

MECHANISMS OF ACTION AND SIGNALING BY STEROID HORMONE ANTAGONISTS
06/01/2003 - 12/31/2015 (PI)
NIH/National Cancer Institute
5R01CA101992-09

TARGETING N-RAS AS A TERAPEUTIC APPROACH TO MELANOMA
09/30/2012 - 09/29/2014 (PI)
Department of Defense/Army Medical Research Acquisition Activity

SYNTHETIC LETHALITY AS A TARGETED APPROACH TO ADVANCED PROSTATE CANCER
03/01/2011 - 02/28/2014 (PI)
Department of Defense/Army

VIRUS-TARGETED THERAPY FOR MALIGNANCIES
09/26/2011 - 08/31/2012 (PI)
Phoenicia Biosciences, Inc. NIH NCI
R43CA153474-01A1

VIRUS-TARGETED THERAPEUTIC FOR EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOMAS
08/01/2009 - 07/31/2012 (PI)
V Foundation

Testing of new HDAC Inhibitors in EBV lymphoma
01/01/2011 - 01/01/2012 (PI)
Hemaquest Pharmaceuticals, Inc.

Showing 10 of 39 results. Show All Results

SWOG - NCI
02/23/2004 - 02/28/2018 (PI)
South West Oncology Group



Yr Title Project-Sub Proj Pubs
2014 Non-Oncogene Addiction as a Targeted Therapy for Pancreatic Cancer 5R21CA164245-02 5
2014 Boston University Cross-Disciplinary Training in Nanotechnology for Cancer 5R25CA153955-05 29
2014 Boston University Cross-Disciplinary Training in Nanotechnology for Cancer 3R25CA153955-05S1 29
2014 Boston University Cross-Disciplinary Training in Nanotechnology for Cancer 3R25CA153955-05S2 29
2013 Non-Oncogene Addiction as a Targeted Therapy for Pancreatic Cancer 1R21CA164245-01A1 5
2013 Boston University Cross-Disciplinary Training in Nanotechnology for Cancer 5R25CA153955-04 29
2013 Boston University Cross-Disciplinary Training in Nanotechnology for Cancer 3R25CA153955-04S1 29
2013 Boston University Cross-Disciplinary Training in Nanotechnology for Cancer 3R25CA153955-04S2 29
2013 Mechanisms of Action and Signaling by Steroid Hormone Antagonists 5R01CA101992-09 17
2012 Boston University Cross-Disciplinary Training in Nanotechnology for Cancer 5R25CA153955-03 29
Showing 10 of 88 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Moos WH, Faller DV, Glavas IP, Harpp DN, Irwin MH, Kanara I, Pinkert CA, Powers WR, Steliou K, Vavvas DG, Kodukula K. A New Approach to Treating Neurodegenerative Otologic Disorders. Biores Open Access. 2018; 7(1):107-115. PMID: 30069423.
     
  2. Bell JA, Galaznik A, Blazer M, Farrelly E, Ogbonnaya A, Raju A, Eaddy M, Fram RJ, Faller DV. Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care. Leuk Lymphoma. 2018 Jun 22; 1-11. PMID: 29932781.
     
  3. Bell JA, Galaznik A, Farrelly E, Blazer M, Murty S, Ogbonnaya A, Eaddy M, Fram RJ, Faller DV, Kota V. Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States. Leuk Res. 2018 Aug; 71:27-33. PMID: 29944984.
     
  4. Lockhart AC, Bauer TM, Aggarwal C, Lee CB, Harvey RD, Cohen RB, Sedarati F, Nip TK, Faessel H, Dash AB, Dezube BJ, Faller DV, Dowlati A. Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. Invest New Drugs. 2018 May 21. PMID: 29781056.
     
  5. Bell JA, Galaznik A, Huelin R, Stokes M, Guo Y, Fram RJ, Faller DV. Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review. Clin Lymphoma Myeloma Leuk. 2018 Jul; 18(7):e303-e314. PMID: 29802009.
     
  6. Bell JA, Galaznik A, Huelin R, Stokes M, Guo Y, Fram RJ, Faller DV. Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2018 Apr; 18(4):e157-e166. PMID: 29475821.
     
  7. Swords RT, Coutre S, Maris MB, Zeidner JF, Foran JM, Cruz J, Erba HP, Berdeja JG, Tam W, Vardhanabhuti S, Pawlikowska-Dobler I, Faessel HM, Dash AB, Sedarati F, Dezube BJ, Faller DV, Savona MR. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood. 2018 Mar 29; 131(13):1415-1424. PMID: 29348128.
     
  8. Hari P, Lin HM, Asche CV, Ren J, Yong C, Luptakova K, Faller DV, Sanchorawala V. Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis. Amyloid. 2018 Mar; 25(1):1-7.View Related Profiles. PMID: 29303358.
     
  9. Moos WH, Faller DV, Glavas IP, Harpp DN, Irwin MH, Kanara I, Pinkert CA, Powers WR, Steliou K, Vavvas DG, Kodukula K. Epigenetic Treatment of Neurodegenerative Ophthalmic Disorders: An Eye Toward the Future. Biores Open Access. 2017; 6(1):169-181. PMID: 29291141.
     
  10. Kodukula K, Faller DV, Harpp DN, Kanara I, Pernokas J, Pernokas M, Powers WR, Soukos NS, Steliou K, Moos WH. Gut Microbiota and Salivary Diagnostics: The Mouth Is Salivating to Tell Us Something. Biores Open Access. 2017; 6(1):123-132. PMID: 29098118.
     
Showing 10 of 281 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 259 publications over 36 distinct years, with a maximum of 16 publications in 1988 and 1995

YearPublications
19831
19842
19855
19867
198715
198816
19896
19909
19919
19923
19935
199410
199516
199613
199710
19987
19999
20007
20017
20029
20034
20042
20055
200612
20076
20089
20099
20104
20117
20125
20134
20146
20154
20165
20173
20188
Contact for Mentoring:


72 E. Concord St Silvio Conte (K)
Boston MA 02118
Google Map


Faller's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department